Humana (HUM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan Langston from TD Cowen maintained a Hold rating on the stock and has a $268.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ryan Langston has given his Hold rating due to a combination of factors concerning Humana’s current financial outlook and strategic initiatives. While the company’s FY25 guidance aligns with previous expectations, there are significant investments aimed at improving margins and regaining favorable Stars ratings, which introduce a level of financial uncertainty. These investments, coupled with ongoing litigation related to the Stars program, indicate potential volatility in Humana’s future performance.
Additionally, despite Humana’s efforts to enhance its Medicare Advantage (MA) margins, there are both positive and negative pressures impacting the company’s financials. While individual MA margins are projected to improve, group MA margins might remain under pressure. Furthermore, the combination of changes in business mix and the effects of the Inflation Reduction Act (IRA) adds complexity to the company’s financial outlook. Therefore, while there is potential for growth, the risks and uncertainties justify a cautious ‘Hold’ stance.
In another report released today, Barclays also maintained a Hold rating on the stock with a $270.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUM in relation to earlier this year.